GLAXOSMITHKLINE PLC Form 6-K September 12, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 September 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Tra	ansaction notification		
	· · · · · · · · · · · · · · · · · · ·		
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowand platform, auctioneer or auction monitor		
a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to instrument; (ii) each type of transaction place where transaction(s) has been cor	; (iii) each date; and (iv) each nducted	
a)	Description of thefinancial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.	
c)	Price(s) and volume(s)	Price(s)Volume(s)£14.97178 (partnership shares)£14.97178 (matching shares)	
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £14.9717	
e)	Date of thetransaction	2018-09-11	
f)	Place of the transaction	London Stock Exchange (XLON)	
b) c)	Details of PDMR/person closely associ Name Position/status Initial notification/ amendment Details of the issuer, emission allowand	Mr R G Connor President, Global Vaccines Initial notification	
2. a)	platform, auctioneer or auction monitor Name		
b) 3.	LEI Details of the transaction(s): section to instrument; (ii) each type of transaction place where transaction(s) has been cor Description of thefinancial instrument	5493000HZTVUYLO1D793 be repeated for (i) each type of r; (iii) each date; and (iv) each nducted	

### ISIN: GB0009252882

b)	Nature of thetransaction	-	n of Ordinary Shares Company's Share lan.
c)	Price(s) and volume(s)	£14.9717	Volume(s) 8 (partnership shares) 8 (matching shares)
d)	Aggregated information Aggregated volume Price	16 Ordina £14.9717	ry Shares
e) f)	Date of the transaction Place of the transaction	2018-09-1 London St	1 tock Exchange (XLON)
<ul> <li>b)</li> <li>c)</li> <li>2.</li> <li>a)</li> <li>b)</li> <li>3.</li> </ul>	Details of PDMR/person closely associ Name Position/status Initial notification/ amendment Details of the issuer, emission allowand platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to instrument; (ii) each type of transaction place where transaction(s) has been con	Mr S Ding Chief Fina Initial noti ce market p GlaxoSmi 5493000H be repeated n; (iii) each nducted Ordinary s ('Ordinary	gemans ancial Officer affication participant, auction thKline plc IZTVUYLO1D793 d for (i) each type of date; and (iv) each shares of 25 pence each Shares')

b) Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £14.9717 8 (partnership shares)
d) Aggregated information	£14.9717 8 (matching shares)

Aggregated volume Price

16 Ordinary Shares £14.9717

2018-09-11

e) Date of thetransaction

- /		
f)	Place of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associ	ated with them ('PCA')
	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowand platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
	LEI	5493000HZTVUYLO1D793
,	Details of the transaction(s): section to	be repeated for (i) each type of
3.	instrument; (ii) each type of transaction	
	place where transaction(s) has been con	
		Ordinary shares of 25 pence each
		('Ordinary Shares')
a)	Description of thefinancial instrument	ISIN: GB0009252882
		Acquisition of Ordinary Shares
b)	Nature of thetransaction	under the Company's Share
-)		Reward Plan.
		$\mathbf{D}_{\mathbf{r}}$
	$\mathbf{D}$	Price(s) Volume(s)
C)	Price(s) and volume(s)	<ul><li>£14.9717 8 (partnership shares)</li><li>£14.9717 8 (matching shares)</li></ul>
		14.9717 8 (matching shares)
•	Aggregated information	
d)		16 Ordinary Shares
	Aggregated volume Price	£14.9717
e)	Date of thetransaction	2018-09-11
ź	Place of the transaction	
f)		London Stock Exchange (XLON)
1	Details of PDMR/person closely associ	ated with them $('PCA')$
		Mr I Miels

- 2. Details of the issuer, emission allowance market participant, auction
- <sup>2.</sup> platform, auctioneer or auction monitor
  a) Name
  b) LEI
  c) GlaxoSmithKline plc
  c) 5493000HZTVUYL01D793
- Details of the transaction(s): section to be repeated for (i) each type of3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of thefinancial instrument ISIN: GB0009252882

b)	Nature of thetransaction	-	n of Ordinary Shares Company's Share an.
c)	Price(s) and volume(s)	£14.9717	Volume(s) 8 (partnership shares) 8 (matching shares)

Aggregated	information
------------	-------------

**J**)

Aggregated volume Price	16 Ordinary Shares
Aggregated volume Thee	£14.9717

e)	Date of thetransaction	2018-09-11
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PC.
--

a)	Name	Mr D S Redfern	
b)	Position/status	Chief Strategy Officer	
c)	Initial notification/ amendment	Initial notification	
2	Details of the issuer, emission allowand	ce market participant, auction	
Ζ.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction	; (iii) each date; and (iv) each	
	place where transaction(s) has been cor	nducted	
	-	Ordinary shares of 25 pence each	
		('Ordinary Shares')	
a)	Description of thefinancial instrument	ISIN: GB0009252882	

b) Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share

#### Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.9717	8 (partnership shares)
	£14.9717	8 (matching shares)

1\	Aggregated information	n	
d)	Aggregated volume Price	16 Ordinary Shares £14.9717	
e)	Date of thetransaction	2018-09-11	
f)	Place of the transaction	London Stock Exchange (XLON)	

/	Name	President, Pharmaceutical Supply	
b)	Position/status	Chain	
c)	Initial notification/	Initial notification	
	amendment	a market participant quotion	
2.	2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been conducted		
		Ordinary shares of 25 pence each	
		('Ordinary Shares')	
a)	Description of thefinancial instrument	ISIN: GB0009252882	
		Acquisition of Ordinary Shares	

b) Nature of thetransaction	under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s)Volume(s)£14.97179 (partnership shares)£14.97179 (matching shares)

Aggregated in	nformation
---------------	------------

d)

Aggregated volume Price

18 Ordinary Shares £14.9717

- 2018-09-11 e) Date of thetransaction
- Place of the transaction f) London Stock Exchange (XLON)
- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources Initial notification/ Initial notification
- c) amendment
- Details of the issuer, emission allowance market participant, auction 2.
- platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of thefinancial instrument ISIN: GB0009252882

b) Nature of thetransaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
	$\mathbf{Price}(s) = \mathbf{Volume}(s)$

c) Price(s) and volume(s)

Price(s) Volume(s) £14.9717 8 (partnership shares) £14.9717 8 (matching shares)

Aggregated ir	nformation
---------------	------------

**A**)

Aggregated volume Price	16 Ordinary Shares £14.9717

- e) Date of the transaction 2018-09-11 Place of the transaction f) London Stock Exchange (XLON)
- 1. Details of PDMR/person closely associated with them ('PCA')
- Mr P C Thomson a) Name President, Global Affairs b) Position/status Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793
- b) LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

a) Description of thefinancial instrument

b)	Nature of thetransaction	-	n of Ordinary Shares Company's Share lan.
c)	Price(s) and volume(s)		Volume(s) 8 (partnership shares) 8 (matching shares)
d)	Aggregated information Aggregated volume Price	16 Ordina £14.9717	ry Shares

e)	Date of thetransaction	2018-09-11
f)	Place of the transaction	London Stock Exchange (XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status
   c) Initial notification/ amendment
   Company Secretary Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
   b) LEI 5493000HZTVUYL01D793 Details of the transaction(s): section to be repeated for (i) each type of
- instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
   Ordinary shares of 25 pence each
- a) Description of thefinancial instrument <sup>('Ordinary Shares')</sup> ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share

Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.9717	8 (partnership shares)
	£14.9717	8 (matching shares)

d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £14.9717
e)	Date of the transaction	2018-09-11
f)	Place of the transaction	London Stock Exchange (XLON)

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: September 12, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc